| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to a compound of formula or a pharmaceutically acceptable salt thereof, wherein G 1 is phenyl or pyridyl, each of which is optionally additionally substituted by one substitute presented by T; G 2 is phenyl, 1,3-thiazolyl or 1,3-oxazolyl, wherein G 2 is bound to G 1 in the para position in relation to a place of attachment of G 1 to group NH in formula (I), wherein G 2 means phenyl, G 3 is bound to G 2 in the para position of G 2 in relation to G 1 , and wherein provided G 2 represents 1,3-thiazolyl or 1,3-oxazolyl, G 2 is bound to G 1 in the position of 5 G 2 and G 3 is bound to G 2 in the position of 2 G 2 ; T in each case is independently specified in a group containing C 1-6 alkyl and halogen; G 3 is presented by formula or by formula ; W 1 is -C(R 3 )(R 4 )-C(R 3 )(R 4 )-, and W 2 represents N; or W 3 represents O; W 4 is -C(R 3 )(R 4 ) -; each R 3 and R 4 is hydrogen; each R 5 and R 6 kis hydrogen; R c and R d together with a carbon atom whereto attached, are a 4-5-member cycloalkyl or monocyclic heterocycle of formula ; wherein one hydrogen atoms attached to the carbon atom of the cycloalkyl ring and monocyclic heterocycle is optionally substituted by a radical specified in a group -C(O)O(R 8 ); W 5 is -CH 2 - or -CH 2 -CH 2 -; W 6 is O or N(R X ), wherein R x is hydrogen, C 1-6 alkyl or -C(O)O(R z ); R Z in each case is independently C 1-6 alkyl; R 8 is hydrogen; L 1 is O; and X is hydrogen, C 1-6 alkyl, or - (CR g R h ) u -C(O)O(R 10 ); or L 1 is -CH 2 - and X is -C(O)OH; R 10 is hydrogen; or Q is G 4 or Y 1 -Y 3 ; or Q is described for formula wherein Z is phenyl; G 4 is benzothiazole or benzoxazole optionally additionally substituted by 1 or 2 substitutes specified in a group consisting of C 1-6 alkyl, halogen and -OR 1 ; Y 1 in each case is independently -C(O)-, -C(O)O- or -C(O)N(R w )-, wherein the right side -C(O)O- and -C(O)N(R w )- of the groups is attached to Y 3 or (CR J R k ) v , Y 3 in each case is independently phenyl, benzyl, piperidinyl or bicyclo[4.2.0]octa-1,3,5-triene, wherein the phenyl and benzyl residues are optionally additionally substituted by 1 or 2 substitutes specified in a group consisting of halogen and haloC 1-6 alkyl; R g and R h in each case is independently hydrogen, or C 1-6 alkyl; R 1 in each case is independently halogenC 1-6 alkyl; R w is hydrogen; and u means 1. n EFFECT: compounds being the type 1 diacylglycerol O-acyltransferase (DGAT-1) enzyme inhibitors. n 7 cl, 1 tbl, 61 ex |